Jane Street Group LLC Purchases New Shares in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

Jane Street Group LLC purchased a new position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,375 shares of the company’s stock, valued at approximately $1,163,000.

Several other institutional investors have also recently made changes to their positions in the company. FMR LLC lifted its holdings in shares of Invesco Pharmaceuticals ETF by 29.4% during the third quarter. FMR LLC now owns 1,057 shares of the company’s stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. Arete Wealth Advisors LLC bought a new position in shares of Invesco Pharmaceuticals ETF during the third quarter valued at $402,000. International Assets Investment Management LLC bought a new position in Invesco Pharmaceuticals ETF in the 2nd quarter worth about $66,000. Joseph Group Capital Management increased its stake in Invesco Pharmaceuticals ETF by 10.8% during the 2nd quarter. Joseph Group Capital Management now owns 13,001 shares of the company’s stock valued at $1,069,000 after purchasing an additional 1,272 shares in the last quarter. Finally, Secure Asset Management LLC bought a new position in shares of Invesco Pharmaceuticals ETF in the third quarter worth approximately $229,000.

Invesco Pharmaceuticals ETF Stock Down 0.7 %

Shares of PJP opened at $83.09 on Monday. The company has a market capitalization of $281.68 million, a P/E ratio of 21.48 and a beta of 0.61. The firm has a 50 day moving average of $85.92 and a 200 day moving average of $85.50. Invesco Pharmaceuticals ETF has a twelve month low of $74.82 and a twelve month high of $89.87.

Invesco Pharmaceuticals ETF Company Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.